LP will put the most into our pockets. None of those BPs have bargaining chips on their shoulders. Have we seen the collaboration trial between Merck and Moderna failing to deliver the results better than the neoadjuvant treatment? When BMS acquired Celgene , the share price was $50. Today its sp is $40.
All in all, LP will bring BPs a platform to treat cold tumors which account for 80% of solid tumors. They are going to make a lot of money too.
Market Data 
Markets 
AI
